Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Greenwich Lifesciences Inc (NQ: GLSI )

14.12 -0.33 (-2.28%)
Streaming Delayed Price Updated: 2:04 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Greenwich Lifesciences Inc

< Previous 1 2 3 Next >
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings
Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of... 
Via Benzinga
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
From Greenwich LifeSciences, Inc.
Via Business Wire
58 Biggest Movers From Friday
Gainers Hagerty, Inc. (NYSE: HGTY) shares jumped 46.5% to close at $15.62. TuanChe Limited (NASDAQ: TC) gained 44.7% to settle at $3.30. IO Biotech, Inc. (NASDAQ: IOBT) shares... 
Via Benzinga
Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
From Greenwich LifeSciences, Inc.
Via Business Wire
The Moonshot Investor: The Insider Track Strategy
Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung's Moonshot Investor series. Investors interested in 
Via InvestorPlace
3 Stocks Insiders Are Snapping Up. Do They Know Something We Don’t?
Insider trading is heavily regulated, but it still happens, and it's worth paying attention to big moves from insiders for potential profits. 
Via InvestorPlace
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Set to Join Russell 2000® Index
From Greenwich LifeSciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021
Upgrades For Chatham Lodging Trust (NYSE: 
Via Benzinga
Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer Recurrence
Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have... 
Via Benzinga
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
From Greenwich LifeSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Tilray (NASDAQ:TLRY) shares incre... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now? 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Insider Buys Greenwich LifeSciences Shares
Greenwich LifeSciences Inc (NASDAQ:GLSI) was trading 4.4% higher from the previous closing price. CEO Patel Snehal filed a Form 4 with the SEC on Wednesday, April 14. The... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $247.0... 
Via Benzinga
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
From Greenwich LifeSciences, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.